Sage Journals: Discover world-class research

Retricted access

Research article

First published 2023-11

Biosimilar to Biosimilar Anti-VEGF Switching for Retinal Diseases

Ashish Sharma, Anat Loewenstein, Nikulaa Parachuri [...]

Journal of VitreoRetinal Diseases

Retricted access

Research article

First published 2024-11

Visual and Anatomic Responses in Patients With Neovascular Age-Related Macular Degeneration and a Suboptimal Response to Anti-VEGF Therapy Switched to Faricimab

Ali Khodor, Stephanie Choi, Tavish Nanda [...]

Journal of VitreoRetinal Diseases

Retricted access

Research article

First published 2013-7

The Results of Switching between 2 Anti-VEGF Drugs,Bevacizumab and Ranibizumab,in the Treatment of Neovascular Age-related Macular Degeneration

Murat Aslankurt, Lokman Aslan, Adnan Aksoy [...]

European Journal of Ophthalmology

Retricted access

Research article

First published 2026-3

Short-term efficacy of faricimab switch on retinal exudative signs in patients requiring frequent anti-VEGF injections : A real-life study

Maïlys Charmasson, Kevin Mairot, Pierre Gascon [...]

European Journal of Ophthalmology

Retricted access

Research article

First published 2023-3

Incidence of adverse events after loading phase of the brolucizumab therapy of neovascular AMD: Real-life evidence in the Czech Republic

Alexandr Stepanov, Jan Studnicka, Miroslav Veith [...]

European Journal of Ophthalmology

Retricted access

Research article

First published 2015-1

Switching Intravitreal anti-VEGF Treatment in Neovascular Age-Related Macular Degeneration

Cem Küçükerdönmez, Faik Gelisken, Efdal Yoeruek [...]

European Journal of Ophthalmology

Retricted access

Research article

First published 2019-5

Clinical Effectiveness of Switching Between Ranibizumab and Aflibercept in Treatment of Neovascular AMD: US Real-World Outcomes

Pravin U. Dugel, Raymond Griner, Alberto Ferreira [...]

Journal of VitreoRetinal Diseases

Retricted access

Research article

First published 2017-5

Clinical Experience of Switching Anti-VEGF Therapy from Ranibizumab to Aflibercept in Age-Related Choroidal Neovascularization

Lauren Van Lancker, Robert Petrarca, Kyros Moutsouris [...]

European Journal of Ophthalmology

Retricted access

Letter

First published 2017-5

Comments to: Clinical Experience of Switching Anti-VEGF Therapy from Ranibizumab to Aflibercept in Age-Related Choroidal Neovascularization

Dan Călugăru, Mihai Călugăru

European Journal of Ophthalmology

Retricted access

Research article

First published 2017-5

Author's Reply to Comments to: Clinical Experience of Switching Anti-VEGF Therapy from Ranimizumab to Aflibercept in Age-Related Choroidal Neovascularization

George Kampougeris

European Journal of Ophthalmology

Search results